Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson
Stacy describes her outcome from stem cell therapy by Dr Harry Adelson for treatment of torn labrum of her shoulder and hip. http://www.docereclinics.com.
By: Harry Adelson, N.D.
Published: Sunday, 3/1/2015 - Updated: 50 seconds ago
BY MARLENEHARRIS-TAYLOR BLADE STAFF WRITER
Hockey legend Gordie Howes star power is raising awareness in the United States and Canada about advances in stem-cell therapies as he continues what is being called a miraculous recovery from a massive stroke.
Those closest to him, including his son, Toledo radiologist Dr. Murray Howe, are convinced the former Detroit Red Wings player would have died if he had not traveled to a medical clinic in Tijuana, Mexico, for an experimental stem-cell treatment not yet available in the United States.
After a debilitating stroke on Oct. 26, Mr. Howe, 86, had a few weeks of slight recovery, but then his health went downhill quickly, said Dr. Howe, director of sports medicine imaging for ProMedica Toledo Hospital. The family had started preparing for his funeral. But that all turned around after he had the adult stem-cell treatment on Dec. 8.
If you saw him now, you wouldnt know he had a stroke, Dr. Howe said.
Its been wonderful. Every day I would say hes a little bit better, and there are little hints of improvement. Certainly in the first month, every day his strength, coordination, and balance were better. He has been eating like a horse. He had lost 20 pounds, and now he has gained back 25 pounds, so he is pretty close to his playing weight now, Dr. Howe said.
Amazing results
In describing his fathers treatment and recovery in the last three months, Dr. Howe does not hesitate to use words such as unbelievable, astonishing, and amazing.
Eight hours after Mr. Howe received what is called a lumbar puncture, where stem cells were injected in the spinal fluid of his lower back by an anesthesiologist, he went from being bedridden and only mumbling short sentences to speaking clearly and walking with assistance, Dr. Howe said.
Read the rest here:
Howe's recovery shows stem-cell advances
In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patients own blood.
Stem cells are so effective because they can become any cell in the body based on their environment.
"Since we started treating patients three years ago, some of the results we have seen have been miraculous," Professor Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, told The Sunday Times.
"This is not a word I would use lightly, but we have seen profound neurological improvements."
During the treatment, the patient's stem cells are harvested and stored. Then doctors use aggressive drugs which are usually given to cancer patients to completely destroy the immune system.
The harvested stem cells are then infused back into the body where they start to grow new red and white blood cells within just two weeks.
Within a month the immune system is back up and running fully and that is when patients begin to notice that they are recovering.
Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter Isla, now two.
But she claims the new treatment has transformed her life.
It worked wonders, she said. I remember being in the hospital... after three weeks, I called my mum and said: 'I can stand'. We were all crying.
See the original post:
'Miracle' stem cell therapy reverses multiple sclerosis
THE contemporary age brings a lot of new things that leave people in awe, amazement, and sometimes, in disbelief and disagreement. One thing that the more advanced technology gave birth to is the controversial Stem Cell Therapy (SCT).
According to mayoclinic.org, SCT is the replacement of damaged or diseased stem cells by injecting or infusing healthy stems into your body.
An article from philstar.com also says that SCT replaces or supports ones degenerating tissues and organs. The stem cells used in this technology are capable of developing into different kinds of cells, thus, are also called master cells.
According to bethematch.org, the diseases that are treatable by SCT are leukemia, bone marrow diseases, inherited immune system disorders, and diseases with poorly functioning red blood cells.
SCT is also used as an anti-aging treatment. Some of the prominent Filipinos have used this therapy to maintain their youthful glow and energy.
In the Philippines, clinics offering SCT have sprouted like mushrooms due to its perceived benefits to the patients. In fact, Makati Medical Center has its Cellular Therapeutics Center, equipped with facilities from Germany, USA, and Japan.
In an article from makatimed.net, it was said that the center has an extensive range of services that boast the remarkable efficacy of stem cells.
Dr. Florencio Q. Lucero who started the use of adult SCT in the Philippines in 2006, was quoted in an article from inquirer.net saying that in the Philippines, most of the customers rich businessmen and public officials who are mostly males.
One of them is Manila Mayor Joseph Estrada. He had his SCT at a clinic in Germany called Villa Medica on April 2012. Another article from inquirer.net said that Estrada had 14 shots of blood from the donor animal, the unborn sheep, on his buttocks.
In the same article, Estrada was quoted saying he could sleep better, his knees are working better, and that his skin has shown its glow.
Originally posted here:
Animal cells for a younger you
Report Details
Translational Regenerative Medicine - new study showing you trends, R&D progress, and predicted revenues Where is the market for regenerative medicine heading? What are the commercial prospects for this market and related technologies? Visiongain's brand new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.
Visiongain's report lets you assess regenerative medicine: cell-based therapies that aim to restore function and regenerate diseased tissues. Our 260 page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from industry specialists informing your understanding and allowing you to assess prospects for investments and sales: Dr Antonio SJ Lee, CEO and Managing Director, MEDIPOST America Inc.
You find prospects for key submarkets and products In addition to analyses of the overall world market, you see revenue forecasts for these three submarkets to 2025: Stem cell therapies Gene Therapies Tissue engineering products
Products that can significantly increase disease-free survival and improve patient tolerance will achieve success. In the long term, we forecast these curative therapies to be adopted by many healthcare systems globally.
Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
See revenue forecasts for products How will leading products perform to 2025 at the world level? Our study forecasts sales of currently marketed and pipeline regenerative medicine products including these: Osteocel Plus Trinity ELITE and Trinity Evolution Prochymal Apligraf Dermagraft ReCell Neovasculgen Glybera Talimogene Laherparepvec (T-Vec)
Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.
Read more from the original source:
Translational Regenerative Medicine: Market Prospects 2015-2025
Manchester scientists have a developed a new method to monitor the effect of anti-cancer drugs on very rare leukemia stem cells. The approach potentially allows doctors to screen patients and personalise their treatment.
The recent development of novel agents has improved outcomes for patients with chronic myeloid leukemia (CML). These so-called tyrosine kinase inhibitors (TKIs) target abnormal proteins caused by commonly found genetic mutations in CML patients. However, the existence of treatment-resistant cancer stem cells -- cells that are able to repeatedly renew the leukemia cell population -- is one way that many patients experience disease recurrence when treatment stops.
Any new drug must therefore be tested on such stem cells, but unfortunately they are only found in very low numbers and are identified by certain cell surface markers. Now researchers at The University of Manchester -- part of the Manchester Cancer Research Centre -- have tested a way to monitor the effect of drugs on small samples of cells.
Professor Tony Whetton, head of the Stem Cell and Leukaemia Proteomics Laboratory who led the study, said: "Current techniques require greater numbers of cells in order to detect changes caused by TKIs. Our study investigated the potential of a new technology platform that can identify changes in very small cell numbers."
The research team looked at an antibody-based approach to detect structural changes in certain proteins, in order to track the effectiveness of the TKI drugs. The instrument used fixes proteins in place and holds them, there allowing for a better signal to be generated from less material. With this approach they found that they could record changes in samples of only a few thousand critically important but rare stem cells.
"This new approach will enable us to test drugs on cells taken from patients, either at presentation or in a clinical trial setting. It has great potential to allow us to implement precision medicine, where patients receive the most appropriate treatment to target their individual tumour," added Professor Whetton.
Story Source:
The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.
Read the rest here:
New approach to assessing effectiveness of anti-cancer drugs
Contact Information
Available for logged-in reporters only
Newswise NEW YORK, NY (February 27, 2015) Researchers have for the first time successfully converted adult human skin cells into neurons of the type that regulate appetite, providing a patient-specific model for studying the neurophysiology of weight control and testing new therapies for obesity. The study, led by researchers at Columbia University Medical Center (CUMC) and at the New York Stem Cell Foundation (NYSCF), was published last month in the online issue of the Journal of Clinical Investigation.
In a separate study, which appeared in the February 10 issue of the journal Development, Kevin Eggan, PhD, Florian Merkle, and Alexander Schier of Harvard University have also succeeded in creating hypothalamic neurons from iPS cells. These neurons help to regulate behavioral and basic physiological functions in the human body, including, in addition to appetite, hypertension, sleep, mood, and some social disorders. The investigators at Columbia and Harvard shared ideas during the course of the research, and these studies are co-validating.
Mice are a good model for studying obesity in humans, but it would better to have human cells for testing. Unfortunately, the cells that regulate appetite are located in an inaccessible part of the brain, the hypothalamus. So, until now, weve had to make do with a mouse model or with human cells harvested at autopsy. This has greatly limited our ability to study fundamental aspects of human obesity, said senior author Rudolph L. Leibel, MD, the Christopher J. Murphy Memorial Professor of Diabetes Research, professor of pediatrics and medicine, and co-director of the Naomi Berrie Diabetes Center at CUMC.
To make the neurons, human skin cells were first genetically reprogrammed to become induced pluripotent stem (iPS) cells. Like natural stem cells, iPS cells are capable of developing into any kind of adult cell when given a specific set of molecular signals in a specific order. The iPS cell technology has been used to create a variety of adult human cell types, including insulin-producing beta cells and forebrain and motor neurons. But until now, no one has been able to figure out how to convert human iPS cells into hypothalamic neurons, said co-author Dieter Egli, PhD, assistant professor of pediatrics (in developmental cell biology), a member of the Naomi Berrie Diabetes Center, and a senior research fellow at NYSCF.
This is a wonderful example of several institutions coming together to collaborate and advance research in pursuit of new therapeutic interventions. The ability to make this type of neuron brings us one step closer to the development of new treatments for obesity, said Susan L. Solomon, CEO of NYSCF.
The CUMC/NYSCF team determined which signals are needed to transform iPS cells into arcuate hypothalamic neurons, a neuron subtype that regulates appetite. The transformation process took about 30 days. The neurons were found to display key functional properties of mouse arcuate hypothalamic neurons, including the ability to accurately process and secrete specific neuropeptides and to respond to metabolic signals such as insulin and leptin.
We dont think that these neurons are identical to natural hypothalamic neurons, but they are close and will still be useful for studying the neurophysiology of weight control, as well as molecular abnormalities that lead to obesity, said Dr. Leibel. In addition, the cells will allow us to evaluate potential obesity drugs in a way never before possible.
This shows, said Dr. Eggan, how improved understanding of stem cell biology is making an impact on our ability to study, understand, and eventually treat disorders of the nervous system. Because there are so few hypothalamic neurons of a given type, they have been notoriously difficult to study. The successful work by both groups shows that this problem has been cracked.
Original post:
Neurons Controlling Appetite Made From Skin Cells
An industry-academic research collaboration yields a new strategy for delivering stem cells to the right location
IMAGE:Researchers identified a small molecule that can be used to program mesenchymal stem cells (blue and green) to home in on sites of damage. view more
Credit: Oren Levy, Brigham and Women's Hospital
Bioengineers from Brigham and Women's Hospital (BWH) with collaborators at the pharmaceutical company Sanofi have identified small molecules that can be used to program stem cells to home in on sites of damage, disease and inflammation. The techniques used to find and test these small molecules may represent important tools in advancing cell-based therapy, offering a new strategy for delivering cells to the right locations in the body. The results of their work appear online this week in Cell Reports.
Through a collaborative research project, the research team tested more than 9,000 compounds, and used a multi-step approach - including a sophisticated microfluidics set up and novel imaging technique - to narrow in on and test the most promising compounds.
"There are all kinds of techniques and tools that can be used to manipulate cells outside of the body and get them to do almost anything we want, but once we transplant cells we lose complete control over them," said co-senior author Jeff Karp, PhD, an associate professor at BWH, Harvard Medical School, and principal faculty at the Harvard Stem Cell Institute. "Through this collaboration, we've been able to identify small molecules that can be used to treat cells outside of the body, programming them to target blood vessels in diseased or damaged tissue."
Small molecules offered the team several advantages including the ability to use a safe and relatively simple procedure to pre-treat the cells before injecting them intravenously.
"There's a great need to develop strategies that improve the clinical impact of cell-based therapies," said co-first author Oren Levy, PhD, an instructor in medicine at BWH. "If you can create an engineering strategy that is safe, cost effective and simple to apply, that's exactly what we need to achieve the promise of cell-based therapy."
Karp's team at the Brigham had previously found that it is possible to use bioengineering techniques to chemically attach molecules to the surface of a cell that act as a GPS, guiding the cell to the site of inflammation. These findings indicated that targeted delivery of cells was possible, but a scalable approach would be needed to impact patients.
"At BWH, we had laid the groundwork. Our collaborators at Sanofi have complementary expertise in screening for small molecules, deep understanding of the biology and unmet needs, and an exceptional ability to bring new therapeutics to the clinic," said Karp. "Defined goals and both teams working seamlessly together created perfect synergy. We learned so much from each other."
More:
Small molecule helps get stem cells to sites of disease and damage
Bengaluru:Feb 27, 2015, DHNS
Two courses of stem cell therapy have helped Ashok Kumar, 59, who suffered from tremors and rigidity due to Parkinsons disease, recover completely, much to the joy of his family. The man was brought inside my cabin in a wheelchair. He was unable to even sit on the chair without support. Today, he walks independently. Stem cell therapy has made it possible for him, said Dr Naseem Sadiq, Director, Plexus Neuro and Stem Cell Research Centre, who began treating Kumar in October, last year.
Previously, medication and surgical procedure were the only treatment option for Parkinsons disease. Medication in the long-term often lacks effectiveness and may cause side effects, while surgery is not always feasible. Lately, stem cell therapy has turned out to be a boon for patients with Parkinsons, Dr Sadiq said.
Kumar is among the few who have benefited from stem cell therapy. However, though the State has been reporting an increase in the number of registered stem cell donors, it is far behind sufficient as the genetic match between donor and recipient could be anywhere between one in 10,000 and one in two million, according to experts.
Speaking to Deccan Herald, Raghu Rajgopal, co-founder, Datri, a registry for stem cell donation, said, The response we get from Karnataka when we conduct stem cell camps is great. We see a lot of people and registering with us.
As many as 6,000 people have registered from the State under the Datri registry. A total of 72,000 people have registered across the country. In Kerala, 11,000 have signed up, the highest so far, he said.
Among the common myths are that by donating stem cells one turns infertile and weak, have increased chances of cancer and also that there would be excess loss of blood, he said.
According to studies, over one lakh people are diagnosed with Leukemia (blood cancer) and other blood disorders every year in India. The Indian Council of Medical Research has predicted that by the end of 2015, Leukemia cases will reach an estimated 1,17,649 and 1,32,574 by 2020. Stem cell therapy is a widely used treatment mechanism for Leukemia.
Go to Top
Read more from the original source:
Stem cell therapy a boon to Parkinson's patients
WELCOME TO PROGENCELL-STEM CELL THERAPIES
Congratulations on taking the first step to improving your health!
PROGENCELL offers stem cell protocols with effective results. Many years of research and experience have resulted in substantial improvements in the health and conditions of patients with various diseases, even where other treatments have failed.
With the highest quality protocols, Progencell uses stem cells directly from the patient (autologous adult stem cells) in order to improve their health. The patients medical condition creates the appropriate environment in the body, resulting in a personalized therapy created specially for him.
We offer patients with certain degenerative diseases an opportunity to improve their health through cellular therapy, correcting their medical conditions from the source by regenerating the tissues and organs that are causing the ailments. Since we use stem cells from the patient, this therapy has no risk of tissue rejection, and minimal secondary effects.
Read more from the original source:
Progencell | Stem Cell Therapy | Tijuana Mexico